Completed
This National Academies public workshop, which was co-hosted by the Forum on Drug Discovery, Development and Translation, and the Forum on Neuroscience and Nervous System Disorders, provided a venue for professionals who typically diagnose ADHD, drug developers, researchers, people with lived experience, and other stakeholders to discuss the diagnosis and treatment of adults with ADHD, explore challenges and opportunities for drug development, and consider strategies for assessing the risks and benefits of ADHD medication treatment in adult populations. The workshop was supported, in part, through a grant (PAR-23-072) from the Center for Drug Evaluation and Research at the FDA.
Featured publication
Workshop
·2024
Attention deficit/hyperactivity disorder (ADHD) diagnosis and treatment among adults has increased over the past decade in the U.S. and globally. Evidence suggests adults with ADHD may be more likely to develop a substance use disorder, and there are concerns that nonmedical use of prescription stim...
View details
Description
A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize a public workshop that will provide an opportunity for professionals who typically diagnose attention-deficit/hyperactivity disorder (ADHD) (e.g., physicians, psychologists, social workers, nurse practitioners, and other licensed counselors or therapists), drug developers, researchers, regulators, patients, and other stakeholders to examine the diagnosis and treatment of adults with ADHD and explore the challenges and opportunities for the development of new therapeutics.
.
The public workshop will feature invited presentations and discussions to:
- Discuss the criteria for diagnosis and treatment of adults with ADHD, taking into consideration health disparities and perspectives of people with lived experience.
- Consider what is known and unknown about the risks and benefits of ADHD medication use in adult populations.
- Share perspectives on the causes, perceptions, consequences, and health equity implications of non-medical use of prescription stimulants, including misuse potential, overdosage, and toxicity.
- Explore challenges and opportunities for the development of new and improved therapeutics for the treatment of ADHD.
- Consider potential strategies for assessing the risks and benefits of ADHD medication treatment in adult populations, including the intersection with opioid use, that support the public health goal of safely and effectively treating adults with ADHD.
The planning committee will organize the workshop, develop the agenda, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
Contributors
Committee
Co-Chair
Co-Chair
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Sponsors
Acadia Pharmaceuticals
Alzheimer's Association
American Brain Coalition
American Neurological Association
Amgen Inc
Association of American Medical Colleges
AstraZeneca
Biogen
Boehringer Ingelheim
Burroughs Wellcome Fund
Cerevel Therapeutics
Cohen Veterans Bioscience
Critical Path Institute
Department of Veterans Affairs
Eisai
Eli Lilly and Company
FasterCures, Milken Institute
Foundation for the National Institutes of Health
Friends of Cancer Research
Gatsby Charitable Foundation
Harmony Biosciences
Janssen Research & Development, LLC
Johnson & Johnson
Karuna Therapeutics
Lundbeck Research USA, Inc.
Medable
Merck & Co., Inc.
Michael J. Fox Foundation for Parkinson's Research
National Cancer Institute
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Eye Institute
National Institute of Allergy and Infectious Diseases
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health BRAIN Initiative
National Multiple Sclerosis Society
National Science Foundation
New England Journal of Medicine
Office of the Director (National Institutes of Health)
One Mind
Paul G. Allen Frontiers Group
Sanofi
Simons Foundation
Takeda
The George & Anne Ryan Institute for Neuroscience at the University of Rhode Island
U.S. Food and Drug Administration
Wellcome Trust
Staff
Carolyn Shore
Lead
Sheena Posey Norris
Lead
Noah Ontjes
Kelsey Babik
Melvin Joppy
